The first round of clinical trials of the Ebola vaccine produced antibodies soon after the injection was completed.
Release date: 2015-04-07 According to the "Central News Agency" report, the first wave of human clinical trials of the Ebola vaccine invented by the National Microbiology Laboratory of Canada has been completed, showing that patients can produce antibodies soon after vaccination. This result is exciting. According to reports, the Canadian Ebola vaccine has been clinically tested in six locations in the United States, Switzerland, Germany, Gabon and Kenya. It has been found that in vaccinated patients, antibodies can be produced quickly in the body. However, whether this vaccine can prevent Ebola infection is still unclear, but according to early signs, this is very likely. The Ebola vaccine, invented by the National Microbiology Laboratory of Canada, is called rVSV-ZEBOV and is produced by Nurem Gene and Merck. An article published in the New England Journal of Medicine describes the first phase of a clinical trial of a vaccine. Two articles reported the results of two clinical trials conducted in the United States and European and African studies. The purpose of the first phase of the clinical trial is to understand whether the experimental drug is safe and the appropriate dosage. Since the experimental sample is too small, it is not yet possible to answer the question "whether it is valid." This answer will not be known until the completion of the Phase 3 trial. Phase 3 trials are currently underway in West Africa. Thomas, the author of two clinical trials in the United States, said that patients who received the vaccine had a very positive signal of immunogenicity after 14 days. By day 28, all patients developed an antibody response. European and African studies indicate that neutralizing antibodies are present in the blood of patients receiving vaccines, which can kill Ebola. This discovery has led experts to believe that the vaccines invented in Canada may prevent the infection of Ebola. A total of 190 volunteers participated in the human clinical trial of the Ebola vaccine in the above six regions. Source: China News Network Fresh Fruit refers to the edible fruits of plants with juicy and mainly sweet and sour tastes. Fruit not only contains rich vitamin nutrition, and can promote digestion. AGOLYN offers a variety of fruits such as Fresh apples, Fuji apples, kiwi, pears, lemons and so on . Fresh Fruit,Fresh Apple,Kiwi Fruit, Fresh Lemon,Fresh Pears Xi'an Gawen Biotechnology Co., Ltd , https://www.agolyn-bio.com